01 mar: Danske Andelskassers Bank A/S – Observationsstatus
04 mar: Indre værdi af SmallCap Danmark A/S er opgjort til 20,6 kr. pr. a..
01-03-2019 14:32:46

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

Copenhagen, Denmark; March 1, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting

the board

decided to grant 6,397 restricted stock units and 19,982 warrants to employees of the company and two of the company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,161.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,161. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 371.67.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 10

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
21 maj - 
Aktier/åbning: Demant og Genmab til tops i grønt marked
13 maj - 
Aktier/middag: Ambu bankes ned i rødt marked
10 maj - 
De mest shortede aktier i april – Pandora kravler op af..
Relateret debat
23 maj - 
Jo, teknologien (UltimAb) var som sådan valideret, så e..
23 maj - 
Dengang var der ingen bevis for den succes teknologien ..
23 maj - 
Præcis, der kommer højst sandsynigt ikke en bud på biks..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
23 maj
GEN
Novartis har 25 blockbustere i pipelinen og milliarder på vej til Genmab AF MARTIN HAVTORN PETERSEN ..
5
20 maj
GEN
Men for at svare på dit spørgsmål vedr. kort og langsigtet vil vi se den brage op igennem taget kort..
4
20 maj
GEN
Vi kan forvente os milepælsbetalinger og synes det er værd at bemærke denne:Eksempelvis estimerede a..
3
21 maj
GEN
Det lugter af en godkendelse lige om hjørnet....
2
20 maj
GEN
Nu er "brage op igennem taget" og "voldsom stigning" jo relativ. Hvad er voldsom stigning - 10 % ? D..
2
20 maj
GEN
Godt skrevet spekulanten89. Jeg er 100% enig. Har også et million beløb i Genmab.. Langsigtet.
2
23 maj
GEN
JNJ kan købe daratumumab ud for 1750... Så kører vi videre med resten... 😀
1
23 maj
GEN
Tja Genmab vil være i sigtekornet for opkøb så langt øjet rækker.
1
23 maj
GEN
Og den her skal da også med:https://medwatch.dk/secure/Medicinal___Biotek/article11368278.ece?fbclid..
1
22 maj
GEN
Den skal lige presses op over 1200, det er et psykologisk stærkt tal så mon ikke vi kan se 1210 idag..
1

Ny storaktionær i DSV: Schweizisk finansgigant har købt op

23-05-2019 16:10:20
Den schweiziske finansgigant UBS er blevet storaktionær i den danske transportkoncern DSV.Det fremgår af en meddelelse fra DSV torsdag.- UBS Group har meddelt, at det har har erhvervet aktier og finansielle instrumenter i DSV, hvilket har bragt den direkte og indirekte ejerandel over 5 pct., fremgår det af meddelelsen.Samlet råder UBS over en ejerandel i DSV på 6,10 pct. af den samlede aktiekapita..

Tyske PMI-tal offentliggjort: "Landets afgørende industrisektor halter stadig"

Relaterede nyheder
23-05-2019 10:42:42
PMI-barometeret over indkøbschefernes syn på aktiviteten i Tyskland udviklede sig overordnet set som ventet i majs foreløbige opgørelse.Tallene var på ingen måde prangende, lyder vurderingen fra Frederik Engholm, der er chefstrateg hos Nykredit.- Det tyske PMI-indeks for fremstillingssektoren viser, at landets afgørende industrisektor stadig halter. Indekset er tæt på uændret - falder fra 44,4 til..

Scandinavian Tobacco Group fremlægger flot regnskab

23-05-2019 08:22:40
En gunstig valutaudvikling og et tidligere opkøb har i årets første tre måneder været med til at løfte resultaterne hos Scandinavan Tobacco Group (STG), der samtidig holder fast i forventningerne til indeværende regnskabsår.Koncernomsætningen endte i første kvartal på 1464 mio. kr., hvilket var mere end de 1285 mio. kr., som omsætningen landede på i samme kvartal sidste år. Det fremgår af kvartals..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Pandora bundprop i cyklisk nedtur for rødt C25
2
Aktier/tendens: Regnskaber i fokus i ventet rød start
3
Torsdagens aktier: Mærsk til tælling inden kvartalstal i surt marked
4
Ny storaktionær i DSV: Schweizisk finansgigant har købt op
5
Svinepriser på himmelflugt giver lettelse hos landmænd - og banker

Relaterede aktiekurser

Genmab A/S 1.199,50 -0,3% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2019 04:57:28
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190514.2 - EUROWEB3 - 2019-05-24 04:57:28 - 2019-05-24 04:57:28 - 1 - Website: OKAY